TCatalyst previously entered into an amended employment agreement with Ms. Miller, pursuant to which she became eligible to receive severance benefits upon a qualifying termination of employment. On October 30, 2023, the Board appointed Charles Wu, Ph.D. as Gyre's Chief Executive Officer, Songjiang Ma as Gyre's President, Ruoyu Chen as Gyre's Interim Chief Financial Officer and Weiguo Ye as Gyre's Chief Operating Officer, each to serve at the discretion of the Board. Thomas Eastling, who is a current director of Gyre, and Ms. Chen are husband and wife.

Except for the foregoing, none of Gyre's other newly appointed officers has any family relationships with any of Gyre's directors or executive officers. Other than the Chen Employment Agreement described below, none of Gyre's newly appointed officers has a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Ruoyu Chen (Age 53). Ms. Chen has worked as senior vice president of finance of GNI USA since 2021.

She is primarily responsible for managing the business of GNI Group in the United States. She has also served as a director of BC since 2018. Ms. Chen has over 20 years of management experience working for multinational companies in departments such as global finance, audit, internal control, taxation, administration and mergers and acquisitions.

From 2014 to 2021, Ms. Chen served as the director of finance and accounting of GNI Group and directly reported to the chief financial officer of GNI Group. In this role, she led investments, financing, financial reporting, and public company disclosure, and was responsible for budget management and financial analysis. From 2012 to 2014, Ms. Chen worked as a manager of the internal audit division at Protiviti Japan.

From 2007 to 2011, she worked at BDO International Japan as an auditor. From 1999 to 2003, Ms. Chen worked at Arthur Andersen Japan, where she participated in strategic consulting projects that implemented the enterprise resource planning systems at several Japanese multinational companies. From 1997 to 1999, she worked as a corporate strategy consultant for Mitsubishi UFJ Consulting and Research Japan.

Ms. Chen holds a bachelor's degree from Nankai University in the PRC and a master's degree from the Graduate School of Economics at Kyoto University in Japan. She is a certified public accountant in Washington State and a CFA Level 2 candidate. Weiguo Ye (Age 46).

Mr. Ye has served as BC's director and president since April 2023, and is primarily responsible for the overall management and operation of BC. Mr. Ye has over 20 years of experience in the pharmaceutical industry. Prior to his current position with BC, Mr. Ye held a series of positions at BC of increasing responsibility, including as a sales director from December 2016 to September 2017, vice president from September 2017 to May 2018, executive vice president from May 2018 to April 2023 and chief operating officer from January 2021 to April 2023.

Prior to joining BC, Mr. Ye had over 18 years of sales management experience. Mr. Ye served as the marketing vice president of Hubei Monyan Pharmaceuticals Co. Ltd. from March 2015 to November 2016 and as the grand area manager and then national sales director of Jiangsu Simcere Pharmaceutical Co.

Ltd. from November 2011 to February 2015. He worked at Shanghai Roche Pharmaceutical Ltd. from August 1997 to November 2011, with his last position as the regional sales manager. Mr. Ye obtained his undergraduate diploma in applied pharmacy through online learning from Peking University in the PRC in July 2009.

He further obtained his executive master of business administration degree (EMBA) from China Europe International Business School in the PRC in August 2021.